Results 91 to 100 of about 12,862 (201)

Outcomes and predictors of treatment response with sofosbuvir plus daclatasvir with or without ribavirin in Egyptian patients with genotype 4 hepatitis C virus infection

, 2018
Ossama A Ahmed,1 Mohamed A Elsebaey,2 Mohamed Hassan A Fouad,1 Heba Elashry,3 Ahmed I Elshafie,1 Ahmed A Elhadidy,2 Noha E Esheba,2 Mohammed H Elnaggar,2 Shaimaa Soliman,4 Sherief Abd-Elsalam3 1Department of Internal Medicine, Ain Shams University ...
Esheba NE, Elshafie AI, Elhadidy AA, Elashry H, Elnaggar MH, Soliman S, Abd-Elsalam S, Ahmed OA, Elsebaey MA, Fouad MHA   +9 more
core  

PPP-adjusted financial impact of treatment coverage for all patients with viraemic HCV infection (for point estimates and uncertainty intervals) with sofosbuvir or ledipasvir/sofosbuvir.

, 2016
PPP-adjusted financial impact of treatment coverage for all patients with viraemic HCV infection (for point estimates and uncertainty intervals) with sofosbuvir or ledipasvir/sofosbuvir.
Peter Beyer (21528), Kees de Joncheere (3166164), Stefan Wiktor (3166158), Kiu Tay-Teo (3166161), Swathi Iyengar (3166167), Sabine Vogler (3131850), Suzanne Hill (160643)   +6 more
core   +1 more source

Treatment Efficacy of Sofosbuvir and Ribavirin Combination at Two Weeks in Chronic Hepatitis C

Journal of Rawalpindi Medical College, 2017
Background:To determine the effectiveness of sofosbuvir plus ribavirin in terms of frequency of negative qualitative PCR at 2nd week of treatment in chronic hepatitis C patients with genotype 3.
Aqsa Naseer
doaj  

Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis

, 2014
BACKGROUND High rates of sustained virologic response were observed among patients with hepatitis C virus (HCV) infection who received 12 weeks of treatment with the nucleotide polymerase inhibitor sofosbuvir combined with the NS5A inhibitor ledipasvir ...
Reddy, K. R., Shiffman, M. L., Schiff, E., Ghalib, R., Kowdley, K. V., Gordon, S. C., Rossaro, L., Bernstein, D. E., Lawitz, E., Fried, M. W., +15 additional authors   +10 more
core   +1 more source

Successful Treatment Using Simeprevir, Sofosbuvir and Rituximab of a Severe Form of Hepatitis C Virus-related Mixed Cryoglobulinemia with Cardiac Involvement

European Journal of Case Reports in Internal Medicine, 2015
Numerous extrahepatic manifestations have been reported in hepatitis C virus (HCV) infection, particularly mixed cryoglobulinemia (MC). MC generally responds to clearance of HCV under pegylated-interferon plus ribavirin treatment.
Rafael Mahieu, Christian Lavigne, Geoffrey Urbanski, Isabelle Fouchard Hubert, Alexandra Ducancelle, Françoise Lunel-Fabiani   +5 more
doaj   +1 more source

Sofosbuvir–daclatasvir improves hepatitis C virus–induced mixed cryoglobulinemia: Upper Egypt experience

, 2018
Amro M Hassan,1 Heba A Osman,2 Hasan S Mahmoud,2 Mohammed H Hassan,3 Abdel-Kader A Hashim,4 Hesham H Ameen5 1Tropical Medicine Department, Faculty of Medicine, Al-Azhar University (Assiut Branch), Assiut, Egypt; 2Tropical Medicine and Gastroenterology ...
Osman HA, Ameen HH, Hassan MH, Hashim AA, Hassan AM, Mahmoud HS   +5 more
core  

Amino Acid Substitutions in Genotype 3a Hepatitis C Virus Polymerase Protein Affect Responses to Sofosbuvir

, 2019
Background & Aims: Sofosbuvir is a frequently used pan-genotype inhibitor of hepatitis C virus (HCV) polymerase. This drug eliminates most chronic HCV infections and resistance-associated substitutions in the polymerase are rare.
McLauchlan, J, Jones, M, Wing, Peter A.C., Smith, D, Aranday-Cortes, Elihu, DaSilva, Sampath, Da Silva Filipe, Ana, Bamford, C, Cunningham, M, Jason Lee, Wing-Liu, Filipe, ADS, Cheung, Michelle, Foster, Graham R., Lee, W-YJ, Irving, W, Barnes, E, McLauchlan, John, Dasilva, S, Bamford, Connor, Aranday-Cortes, E, Ansari, A, Wing, Peter, Barnes, Eleanor, Jason Lee, W-Y, Cunningham, Morven, Smith, David, Ansari, Azim, Jones, Meleri, Cheung, M, Foster, GR, Irving, William, Wing, PAC, Da Silva Filipe, A, Cunningham, Morvan, Lee, Wing-Yiu Jason   +34 more
core   +1 more source

Sofosbuvir/Velpatasvir/Voxilaprevir: A Review in Chronic Hepatitis C

, 2018
Compliance with Ethical StandardsFunding: The preparation of this review was not supported by any external funding.Conflicts of interest: Young-A Heo and Emma Deeks are salaried employees of Adis/Springer, are responsible for the article content and ...
Young-A Heo (4077493), Emma D. Deeks (4985339)   +1 more
core   +1 more source

Autochthonous acute hepatitis E: treatment with sofosbuvir and ribavirin [PDF]

, 2018
Introduction: Hepatitis E virus (HEV) is an emerging cause of autochthonous-acute-hepatitis and acute-on-chronic-liver-failure in western countries. Treatment is not routinely used, despite ribavirin has a good antiviral effect.
Esvan, Rozenn, Volpicelli, Lorenzo, De Angelis, Maurizio, Garbuglia, Anna Rosa, Palazzo, Donatella, Biliotti, Elisa, Franchi, Cristiana, Spaziante, Martina, Taliani, Gloria   +8 more
core   +1 more source

Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection

, 2015
BACKGROUND: In phase 2 trials, treatment with the combination of the nucleotide polymerase inhibitor sofosbuvir and the NS5A inhibitor velpatasvir resulted in high rates of sustained virologic response in patients chronically infected with hepatitis C ...
Ruane, Peter, Agarwal, Kosh, Osinusi, Anu, Han, Lingling, Thompson, Alex, Mo, Hongmei, Afdhal, Nezam, Towner, William J, McHutchison, John G, Roberts, Stuart K, Patel, Keyur, Cooper, Curtis, Dvory-Sobol, Hadas, Mazzotta, Francesco, Rosenberg, William, Lawitz, Eric, Mangia, Alessandra, Tran, Tram T, Conway, Brian, McNally, John, Gane, Edward J, Shiffman, Mitchell L, Wang, Jing, Brainard, Diana M, Reau, Nancy, Bräu, Norbert, Pianko, Stephen, Sulkowski, Mark, Foster, Graham R, Berg, Thomas, Gordon, Stuart C, Asselah, Tarik, Stedman, Catherine AM, Bourlière, Marc, Zeuzem, Stefan   +34 more
core